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Synopsis/Precis 35 words 
Contrast sensitivity is considerably impaired under low light conditions in early disease stages of 
MacTel. It might aid earlier detection of the condition and also be useful as an additional outcome 
measure in interventional trials.  
  
ABSTRACT 
Background/Aims 
Macular pigment optical density (MPOD) is centrally depleted early on in macular 
telangiectasia type 2 (MacTel). Contrast sensitivity might be related to MPOD. Therefore, CS 
might be impaired in early MacTel. The effect of low luminance was assessed on both CS 
and best corrected visual acuity (BCVA). 
Methods  
Cross-sectional study. Pelli-Robson charts were used for CS testing at 1m in photopic (110 
lux) and mesopic (1 lux) conditions. BCVA was tested with ETDRS charts, low luminance 
visual acuity (LLVA) with a 2.0-log unit neutral density filter. MPOD was obtained with dual 
wavelength autofluorescence. 
Results 
103 eyes of 52 MacTel patients (mean age 62.9± sd 10.2, range 35-77) were compared with 
34 healthy eyes of 17 controls (mean age 65.2 ± sd 7.4, range 53-78). CS was significantly 
lower in eyes with MacTel. This impairment was higher in low light conditions (LL-CS). Eyes 
with early MacTel stages had significantly lower LL-CS than controls, but normal (photopic) 
CS. The results were similar but less pronounced for BCVA/LLVA. Decrease of CS was 
correlated with loss of MPOD. 
Conclusions 
Low light conditions have a detrimental effect on visual performance in MacTel. Impaired CS 
might correlate to MPOD depletion as a pathognomonic finding in MacTel. Functional 
impairment might precede structural disintegration, indicating dysfunction on a cellular 
level. The applied tests might be useful as additional functional assessments in clinical 
routine and as outcome measures in future interventional clinical trials.  
  
INTRODUCTION 
Macular telangiectasia type 2 (MacTel) is a bilateral disease with characteristic clinical 
features in funduscopy, fluorescein angiography, fundus autofluorescence, and spectral 
domain optical coherence tomography (SD-OCT).1 Visual symptoms typically start in the fifth 
and sixth decade of life, usually with reading problems and/or metamorphopsia.2-4 The 
impaired reading performance, often despite well preserved central visual acuity, may be 
explained by compromised and progressive paracentral retinal dysfunction with 
characteristic paracentral scotomata.5-7  
Recently, investigational clinical trials have been initiated. An intraocular implant with ciliary 
neurotrophic factor (CNTF) secretion has been used in a phase-2-trial that has recently been 
completed. In this trial, the loss of ellipsoid zone on OCT imaging is used as a surrogate 
measure for disease progression as it has been shown to correlate well with functional loss 
in microperimetry.8,9 However, potential routine clinical outcome measures of macular 
function other than visual acuity and microperimetry testing, such as contrast sensitivity and 
low luminance visual acuity, have not yet been explored in detail.  
The most consistent finding in eyes with MacTel is the loss of macular luteal pigments.10,11 
Although the function of macular pigment is debated, there is a general consensus that it 
reduces light scatter in green/blueish light conditions due to its absorption maximum in the 
blue spectrum.12 This is thought to improve contrast sensitivity, and indeed some studies 
indicate an association of macular pigment optical density (MPOD) and contrast sensitivity: 
Recently, two prospective trials with macular pigment supplementation showed a 
statistically significant improvement of contrast sensitivity of lower to medium spatial 
frequencies with increasing macular pigment (MP) levels.13,14  
  
A potential association between macular pigment density and contrast sensitivity has not 
yet been investigated in MacTel.  
We hypothesized that that contrast sensitivity and low light visual acuity are disturbed 
earlier than best corrected visual acuity. Secondly, we hypothesized that the reduced 
macular pigment density in patients with MacTel would result in reduced contrast 
sensitivity. Using simple, reliable and cost-effective methods such as ETDRS and Pelli-
Robson charts, our intention was to investigate if those tests might be useful as additional 
clinical endpoints in future interventional trials.  
  
METHODS 
Patients and Staging 
Patients of the MacTel Natural History and Observation Study (NHOS) were examined in the 
University Eye Hospital Bonn, Germany. The study was conducted in accordance with the 
Declaration of Helsinki, institutional review board (IRB) approval had been obtained, and 
informed consent was obtained from all participants. Eyes were divided into eyes with 
visible morphological changes in any imaging modality and eyes without any changes (‘stage 
0’). Naturally, it was only possible to classify an eye as ‘stage 0’ in the presence of a definite 
MacTel diagnosis in the fellow eye-this was based on the assumption that MacTel is a 
bilateral disease. Controls were age matched and had no evidence or history of retinal 
diseases.  
Contrast sensitivity  
Monocular contrast sensitivity testing was performed on both eyes with Pelli Robson Letter 
charts at a test distance of 1m with added correction for near distance according to the 
manufacturer's instructions.15 Testing was performed under both photopic and mesopic 
light conditions (mean room illumination set at 110 lux and 1.0 lux, respectively).  
Illumination was determined at several locations within the consultation room using a 
calibrated Light Meter Lux 840021 (Sper Scientific, Scottsdale, USA). Individuals underwent 
10 minutes of light adaptation in the respective light conditions prior to testing. Two 
different test charts were used in alternating manner, and mesopic testing was conducted 
prior to photopic testing, in order to reduce memorisation effects. The contrast sensitivity 
score was calculated as proposed by Pelli and Robson, and therefore steps of 0.15 log units 
were obtained. Measurement of contrast sensitivity under low light conditions were termed 
  
‘low light contrast sensitivity’ (LLCS) as opposed to those under photopic conditions (CS). 
The relative deficit between CS and LLCS was termed ‘low luminance deficit of contrast 
sensitivity’ (LLD-CS). 
Low luminance deficit 
Monocular BCVA and low luminance visual acuity (LLVA) were measured in both eyes at a 
test distance of 4m by standard Early Treatment of Diabetic Retinopathy Study (ETDRS) 
protocols. LLVA was measured and analyzed according to Sunness et al.,16 using a 2.0-log 
unit neutral density ﬁlter placed in front of each eye, using the same ETDRS charts. Low 
luminance deﬁcit of visual acuity (LLD-VA) was deﬁned as the difference between LLVA and 
BCVA. BCVA, LLVA and LLD-VA were expressed in logMAR.  
Macular pigment optical density 
Macular pigment optical density (MPOD) was measured using dual wavelength 
autofluorescence using the HRA Spectralis (Heidelberg Engineering, Heidelberg, Germany) 
and the corresponding software (HEYEX, version 1.9.10.0, HRA/Spectralis Viewing Module 
6.0.13.0). A four second video of simultaneous green and blue autofluorescence was 
obtained and then the MPOD map created following the manufacturer's standard of 
procedure. Loss of MPOD was graded into three classes of increasing MPOD loss, suggested 
by Zeimer et al.17 In brief, class 1 showed MPOD loss limited to the temporal macula; in class 
2, MPOD loss affected the foveola and extended into the nasal part of the macula; class 3 
was defined as a complete MPOD loss with or without a ring of increased MPOD at 5 to 7 
eccentricity.  
  
 
Statistical analysis 
Statistical significance was assessed using linear mixed models. Each model included a 
random intercept to take into account the correlation within subject observations as well as 
a fixed term to take into account potential differences between right and left eyes. All 
statistical analyses were performed using the R statistical software (R development Core 
Team, Vienna, Austria). All statistical results from the linear mixed model are presented by 
showing the fixed effect term ‘b’ which indicates the mean increment in the studied 
phenomenon for a unit change in the the condition of interest. A p-value < 0.05 was 
considered as significant. The 2D-density contour-plots were calculated with the 2D-kernel 
density estimation function kde2d from the MASS package in R (version 3.3.1).   
RESULTS 
Out of 122 eligible participants of the NHOS, we were able to recruit 52 patients (mean age 
62.9± sd 10.2, range 35-77). The control cohort consisted of 34 eyes of 17 controls (mean 
age 65.2 ± sd 7.4, range 53-78). Contrast sensitivity 
One eye of a MacTel patient was excluded from contrast sensitivity and visual acuity 
analysis because of a non-plausible test result (increase of contrast sensitivity under 
mesopic conditions). Table 1 summarises the results of contrast sensitivity and visual acuity 
testing. The remaining 103 eyes with MacTel had significantly impaired photopic and 
mesopic contrast sensitivity when compared to controls (b=–0.237, p-value<0.001 and b=–
0.373, p-value<0.001). This impairment was higher in mesopic condition when compared 
with photopic conditions (b=-0.136, p-value=0.003), shown in figure 1. Eyes with higher or 
  
normal photopic contrast sensitivity had a pronounced and significantly higher impairment 
of contrast sensitivity in mesopic conditions when compared with controls (b=–0.259, p-
value<0.001). ‘Stage 0’ eyes (n=6) were within this group (figure 1, crosses). 
 
MacTel eyes showed a significantly decreased BCVA (b=0.2801, p-value<0.001) and LLVA 
(0.346, p-value<0.001). BCVA was significantly associated with CS and LL-CS (figure 3, left 
panel, b=-0.356, p-value<0.001 and b=-0.275, p-value<0.001).  
 LLD-VA was significantly higher in MacTel eyes when compared with controls (b=0.065, p-
value=0.006). However, the absolute differences were not very pronounced. Figure 2 shows 
the normalized loss of function under low light/ low luminance conditions for both contrast 
sensitivity (LLD-CS) and visual acuity (LLD-VA). Macular pigment optical density (MPOD) 
MPOD measurement was discarded in two eyesdue to poor quality MPOD images. Of the 
remaining 102 eyes, 6 eyes (6%) were classified as MPOD class 0, lacking any visible MPOD 
reduction. 17 eyes (17%) as class 1, 33 eyes (32%) as class 2 and 46 eyes (45%) as class 3. 
Figure 3 shows the contrast sensitivity of eyes with different classes of macular pigment 
loss. Mesopic contrast sensitivity was similarly impaired in all eyes. Photopic contrast 
sensitivity decreased with higher MPOD classes: We found a significant decrement in 
contrast sensitivity in photopic condition for each unit increment in MPOD class (b=-0.068, 
p-value<0.001). Although present, this decrement was not significant in mesopic light 
condition (b=-0.025, p-value=0.196). Importantly, significance of MPOD classes on contrast 
sensitivity vanished completely when correcting for BCVA indicating that the effect of MPOD 
  
on contrast sensitivity in photopic condition might be connected to its correlation with 
BCVA.  
  
DISCUSSION 
Summarizing the above results, eyes with MacTel showed a generalized impairment of 
contrast sensitivity which increased in low light conditions (increased LLD-CS). This was 
found in eyes without detected morphological changes, and in eyes with normal BCVA and 
no absolute scotoma in microperimetry testing. A similar, but markedly less pronounced 
effect was found with LLD-VA.  
Our results indicate that low light has a detrimental effect on visual function in MacTel. This 
is detectable as significant impairment of contrast sensitivity and increased low luminance 
deficit when compared with healthy eyes. This effect is most pronounced in early disease 
stages: All eyes (early and late stages) seem to have similarly low levels of mesopic contrast 
sensitivity. While photopic contrast sensitivity and BCVA is normal in eyes with early disease 
stages, it is already impaired in eyes with later disease stages. Thus, in our figures 2 to 4, 
eyes with early stages are found rather in the bottom left of the graphs, whereas eyes with 
late stages are more towards the top right. An increased impairment of contrast sensitivity 
under mesopic conditions (increased LLD-CS) has been shown in other macular diseases 
including AMD and diabetic retinopathy as well as in neurological disorders such as 
Parkinson disease and multiple sclerosis (reviewed in 18). More importantly, we found a 
lower (mesopic) contrast sensitivity in eyes without visible structural changes, pointing 
towards cellular stress on a micro-cellular level (e.g., impaired metabolism), ultimately 
leading to structural changes (and in the end cell atrophy). Impaired contrast sensitivity 
without morphological changes was also found in patients with diabetes.19 Interestingly, 
diabetes seems to occur more frequently in patients with MacTel, 1 hinting towards 
common metabolic dysregulations at least in some patients – likewise leading to similar 
  
functional impairments. We were surprised by the degree of contrast sensitivity impairment 
in seemingly unaffected MacTel eyes. Charbel Issa and Heeren have recently shown that 
those eyes revealed a reduced Stiles-Crawford-effect.20 Cone misalignment might cause 
metabolic stress, as recently hypothesized by Eckmiller 21 and metabolic changes might 
impair contrast sensitivity.22 However, the implications of these findings still need further 
investigations.  
The difference between MacTel eyes and controls was less pronounced in low luminance 
visual acuity testing. As both groups showed a marked overlap, LLD-VAmight not be useful 
in order to differentiate between affected and non-affected eyes. We can only speculate 
why the LLD-VA is less markedly increased than LLD-CS. A possible explanation might be that 
visual acuity testing is based on high spatial frequencies with maximum contrast (> 85%), 
and therefore can be considered a special case of contrast testing. Even when the 
luminance of both background and stimuli are reduced, those letters still yield a rather high 
contrast, and therefore the effect of visual impairment might not be so pronounced. A 
preceding loss of rod function 10,23 might also contribute to impaired contrast sensitivity in 
mesopic condition, especially in the spatial range of Pelli-Robson letters that overlap with 
the range of maximum rod contrast sensitivity.24 Further studies are needed to specify the 
affection of contrast sensitivity in different spatial frequencies, especially under mesopic 
conditions. 
Our study showed a cross sectional correlation between the pattern of macular pigment 
loss and contrast sensitivity. Although a longitudinal study would be preferable to show 
correlations in changes of both, this is very challenging in reality. First, the disease is only 
very slowly progressing and there is currently not much data available about the 
  
longitudinal natural history of macular pigment density. In fact, to our best knowledge there 
is currently no data published on the change of macular pigment patterns over time. 
Secondly, supplementation with Lutein and Zeaxanthin showed no change of central 
accumulation in two independent studies.17,25 It is not surprising that Choi et al were not 
able to find a correlation of contrast sensitivity and macular pigment in their study which 
only included eyes with complete loss of central macular pigment (‘MPOD class 3’). 
Although MP supplementation was shown to increase the optical density at 5-7 degree 
eccentricity, this change is unlikely to influence contrast sensitivity, as the latter is usually 
tested within the central 10 degrees and not beyond. On this background, a cross sectional 
approach in order to test for correlation between contrast sensitivity seems a viable option 
in our opinion. . However, it is possible that there might be another factor which leads to 
decreased luteal pigment, BCVA and contrast sensitivity alike.  
Potential limitations of our study include the use of a categorical variable for MPOD. A 
continuous variable would certainly have been preferable for the correlation analysis with 
contrast sensitivity and BCVA. The reason for using (categorical) MPOD patterns of 
increasing macular pigment loss instead was the problematic and rather unreliable 
quantification of MPOD based on the images. The method, as good as it is, is very 
dependent on factors such as retinal illumination, eye movements during image acquisition 
and lens opacity and the generalized macular pigment density in the more peripheral retina. 
This led to not entirely plausible large ranges of MPOD in our cohort. On the other hand, we 
have observed that the patterns of macular pigment loss were very reproducible (data not 
shown).  
  
A smaller limitation of our study is the limited number of available Pelli-Robson charts which 
might have led to a memorizing effect. We tried to reduce this bias by alternating and 
testing first under mesopic and then under photopic conditions.  
Also, the statistical power is only limited towards the six eyes with 'unilateral' MacTel (stage 
0). Unfortunately, not many of those cases have been identified yet, and our results might 
be affected by small numbers. We are currently continuing to identify further unilateral 
cases in order to validate our results and gain further insights. 
Overall, our results underscore the importance of background light levels for the visual 
performance in patients with MacTel. Their contrast perception is impaired, and even more 
so in low light levels (simulation in Figure 4). The impairment  of contrast vision under 
reduced light conditions might be correlated to loss of macular pigment optical density as a 
pathognomonic finding in MacTel. Our results suggest that even eyes without impairment in 
visual acuity testing and/or without morphological changes might already show impaired 
contrast sensitivity . Although we were not able to pinpoint the functional loss to a particular 
structural or cellular dysfunction, the applied tests have the advantage to be well established, 
cost-effective, quick and easy to perform. They would, therefore, qualify to be used as 
additional functional assessments both in clinical routine and potentially as outcome 
measures in future interventional clinical trials.
  
Table 1: Summary of results 
  
Measure 
Controls   
n = 34 
MacTel  
n = 103* 
‘Photopic’ contrast sensitivity (CS) 1.87±0.13 1.63±0.22 
‘Mesopic’ contrast sensitivity (LL-CS) 1.58±0.13 1.21±0.19 
Low luminance deficit of contrast sensitivity 
(LLD-CS) 
0.28±0.11 0.42±0.19 
Best corrected visual acuity (BCVA), logMAR -0.04±0.08 0.25±0.28 
Low luminance visual acuity, logMAR 0.16±0.12 0.51±0.26 
Low luminance deficit of visual acuity (LLD-VA) 0.20±0.07 0.26±0.11 
* one eye was removed from analysis because of non-plausible test results (increase of 
contrast sensitivity in low luminance conditions). p-Value <0.001 for all measures except for 
LLD-VA (p-value = 0.006) 
  
  
 
Figure 1:  
Every dot represents an individual eye, jitter was applied in order to show every data point. The 
density contour lines show the estimated density distribution. The y-axis shows the loss of contrast 
sensitivity (CS) and best corrected visual acuity (BCVA) in low light/ low luminance conditions (LLD-
CS/ LLD-VA). It is expected that all eyes have an impaired CS/VA under low light conditions. Controls 
and MacTel eyes do hardly overlap, meaning a relatively higher functional impairment for MacTel 
eyes when compared with controls, even when photopic contrast sensitivity is normal. 
Figure 2:  
Low luminance deficit of contrast sensitivity (LLD-CS) and low luminance deficit of visual acuity (LLD-
VA). In both cases, there is an increasing loss of function with decreasing best corrected visual acuity 
(BCVA). The figures show normalized values (z-scores), based on the mean/sd of the full sample 
(controls and MacTel eyes). Eyes with MacTel and normal BCVA showed both higher LLD-CS and 
higher LLD-VA than healthy control eyes. However, this effect was more pronounced for LLD-CS: The 
probability of having higher LLD than controls is higher for CS than for VA. (The density contours 
show the estimates of the probability of distribution) Eyes with stage 0 disease (crosses) had 
markedly increased LLD-CS, but less clearly increased LLD-VA when compared with controls.  
Figure 3  
Blue circles represent one individual eye with MacTel (jitter was applied). Density contour lines show 
the estimated density distribution. The red transparent dot shows the point with the highest density 
of healthy control eyes as shown in figure 1. The higher the class of macular pigment optical density 
(MPOD) the lower was photopic contrast sensitivity. Loss of contrast sensitivity, however, showed a 
tendency to become lower with increasing classes, indicating that mesopic contrast sensitivity is 
impaired early on and also indicating a possible ‘floor effect’ of mesopic contrast sensitivity in 
MacTel. 
  
 
 
Figure 4  
Simulation of contrast vision for MacTel patients. We do not see a structural difference between the 
healthy fundus on the left, and the seemingly ‘unaffected’ fellow eye of a patient with macular 
telangiectasia type 2 (MacTel) on the right. The macular pigment measurement of this eye can be 
seen in Figure 3 (example image for ‘class 0’). Mesopic contrast sensitivity of this eye was almost 
50% lower than the mean mesopic contrast sensitivity of our controls. This difference of contrast 
perception is simulated for photopic conditions (upper row) and mesopic conditions (lower row). A 
stimulus that is fairly easily perceptible with healthy eyes, is hardly visible for eyes with MacTel. The 
bottom right shows a contrast of 4.6%, which was the contrast threshold of this eye (log contrast 
sensitivity 1.35). Mean contrast threshold in controls in mesopic condition was around 2.5% (log 
contrast sensitivity 1.6). The simulation is based on the simplifying assumption that the perception 
of contrast differences behaves proportional throughout all contrast ranges. 
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